Medical/Pharmaceuticals
REPROCELL Signs Agreement to Prospectively Collect Samples for IFF's Microbiome Study
BELTSVILLE, Md., April 20, 2022 /PRNewswire/ -- REPROCELL and IFF have entered into a clinical services agreement where in, REPROCELL will provide various types of samples for the study titled"Isolation and Characterization of Multiple Microbial Species from Diverse Healthy Adults (IsoMic)". The ...
2022-04-20 21:00
1851
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
SHANGHAI, April 20, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced the Investigational New Drug (IND) clearance from the National Medical Products ...
2022-04-20 18:30
2363
Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on April 27 at 10:00 CEST
STOCKHOLM, April 20, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the presentation o...
2022-04-20 18:28
1535
Samsung Biologics completes full acquisition of Samsung Bioepis
* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...
2022-04-20 14:45
1679
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic. The purpose of...
2022-04-20 14:04
1610
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...
2022-04-20 10:27
1291
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...
2022-04-20 08:00
1505
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
NEW YORK and HONG KONG, April 20, 2022 /PRNewswire/ -- Treadwell Therapeutics (" Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced today the appointment of J.D. Mowery as Chief Operating Officer (COO). Reporting into...
2022-04-20 04:30
1764
FIRST PATIENT WITH BASAL CELL CARCINOMA TREATED IN NEW FOCUSED ULTRASOUND STUDY: TOOsonix A/S
The dermatology departments at Bispebjerg and Roskilde Hospitals, University of Copenhagen, Denmark, initiate pioneering treatment of the world's most common cancer with a new convenient, minimal-pain and easy-to-operate modality for skin oncology. HOERSHOLM, Denmark, April 19, 2022 /PRNewswire...
2022-04-19 21:08
1963
Excelra Makes Strategic Investment in Anlitiks, a Disruptive HEOR and RWE Technology-led Consulting Company
HYDERABAD, India and BOSTON, Mass., April 19, 2022 /PRNewswire/ -- Excelra, a leading global Data and Analytics provider for Life Science organizations, has announced a strategic majority investment in Anlitiks, a young and rapidly growing technology company in the value and evidence domain. The...
2022-04-19 21:00
2624
Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Prep for Single-Cell DNA Analysis
MSKCC lab paired Tapestri and Singulator 100 to demonstrate automated nuclei extraction workflow for fast and reliable nuclei prep for single-cell DNA analysis SOUTH SAN FRANCISCO, Calif., April 19, 2022 /PRNewswire/ -- Mission Bio, Inc. , the pioneer in high-throughput single-cell DNA and multi-...
2022-04-19 20:00
1647
SMART Medical Systems' G-EYE® Colonoscope is now FDA Cleared on Olympus' PCF Colonoscope Series, Making it Available in the United States on the Commonly Used Models of All Leading Endoscopy Brands
- FDA has approved the use of G-EYE® with Olympus' 510(k) cleared PCF colonoscopes - RA'ANANA, Israel, April 19, 2022 /PRNewswire/ -- SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today announced an additional FDA clearance for its G-EYE® Colonoscope...
2022-04-19 20:00
1753
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
* Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older inJapan * Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
2022-04-19 19:15
2200
Gastroenterology: NTC submits marketing authorisation application for KLEERKOL® in EU
MILAN, April 19, 2022 /PRNewswire/ -- NTC Srl, R&D driven pharmaceutical company with headquarters inItaly announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its development product NTC015 (Kleerkol®) for bowel preparation fo...
2022-04-19 18:00
1733
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with global intel...
2022-04-19 16:50
2214
Mediscience Espoir Inc. Looking for OEM Customers, Technical Business Partners and Sales Agents for Oxygen Clathrate Hydrates and Oxygen Solutions
KAWASAKI, Japan, April 19, 2022 /PRNewswire/ -- Mediscience Espoir Inc. announced onApril 19 that it is looking for U.S. partners for oxygen clathrate hydrates and oxygen solutions based on its proprietary technology. The company obtained "Substance Patent" in the United States (US 10,913,037 B2)...
2022-04-19 14:00
1191
Translumina launches VIVO ISAR, its Dual-Drug Polymer-free Coated Stent (DDCS) in International markets
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey NEW DELHI and HECHINGEN, Germany, April 19, 2022 /PRNewswire/ -- Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used...
2022-04-19 14:00
2140
Pondok Indah Hospital Group first in Indonesia to achieve HIMSS EMRAM Stage 6
JAKARTA, Indonesia, April 19, 2022 /PRNewswire/ -- HIMSS announced today that Pondok Indah Hospital Group has become the first healthcare provider inIndonesia to achieve Stage 6 on the HIMSS Electronic Medical Record Adoption Model (EMRAM). The eight-stage EMRAM measures clinical outcomes, patien...
2022-04-19 13:59
1913
GILEAD SCIENCES AND NATIONAL FOUNDATION OF DIGESTIVE DISEASES SET OUT TO STRENGTHEN LEARNING, ACCESS TO LIVER HEALTH EDUCATION IN SINGAPORE
-- Gilead Sciences supports National Foundation of Digestive Diseases with grant funding to improve liver health education inSingapore as part of its Asia Pacific ALL4LIVER Grant -- -- The National Foundation of Digestive Diseases gets digital upgrade to enhance liver health awareness and educa...
2022-04-19 11:00
1862
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for international investors, during which the executive leaders revealed Simere's R&D strategy, and gave an update...
2022-04-19 10:28
1820
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 282 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 277 media titles]
2024-04-19 13:25
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3819
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
3618
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3085
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3023